Related Experiment Video
Updated: May 10, 2025

Rapid High-throughput Species Identification of Botanical Material Using Direct Analysis in Real Time High Resolution Mass Spectrometry
Published on: October 2, 2016
Changes over time in novel benzodiazepines contributing to fatal overdoses in Victoria, Australia
Jennifer L Schumann1,2,3, Rebekka Syrjanen2, Jeremy A Dwyer2,4
1Victorian Institute of Forensic Medicine, Melbourne, Australia.
Introduction:
Novel benzodiazepines (NBZN) have increased in availability and use since the mid-2000s, with a corresponding rise in associated harms including deaths.
Methods:
The study used data from the Victorian Overdose Deaths Register to explore which specific NBZNs and combinations of NBZNs contributed over time to Victorian overdose deaths between January 2009 and December 2023.
Results:
There were 140 NBZN-involved overdose deaths in Victoria, with an observable increase in deaths from 2019 onward. Eight main groupings of deaths in time were identified, based on contributing NBZNs. Key groupings included etizolam-related deaths between 2019 and 2021, followed by flualprazolam and clonazolam deaths, and later, bromazolam and clobromazolam combinations in 2022-2023.
Discussion And Conclusions:
These findings reflect the transiency of NBZNs in Victoria's unregulated drug market and highlight the importance of certain harm reduction measures in addressing increasing NBZN use. These include public education around the risks of using benzodiazepines not dispensed from pharmacies and the use of drug checking services to assist people obtaining benzodiazepines from unregulated drug markets.
Related Concept Videos
Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
CNS Depressants: Barbiturates and Benzodiazepines
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Desensitization and Tachyphylaxis
Sedatives and Hypnotics Drugs: Barbiturates
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...

